Review
Copyright ©The Author(s) 2023.
World J Hepatol. Feb 27, 2023; 15(2): 180-200
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.180
Table 2 Clinical trials for evaluating the efficacy of compounds in liver disease
Treatment
Trial number
Phase
Aims or results
CurcuminNCT029081522-3To investigate the effects of curcumin supplements on metabolic factors and hepatic fibrosis in NAFLD patients with T2DM
NCT041097422To test the effect of curcumin in pediatric patients with NAFLD
EmpagliflozinNCT038674872To evaluate the preliminary feasibility, initial efficacy, and safety of empagliflozin as a SGLT2 inhibitor for treating NAFLD in adolescents with obesity
NCT046422614To test the effects of empagliflozin on reducing hepatic fat content as measured by MRI-PDFF in NAFLD patients without DM
GastrodinNCT040358244To treat hypertension together with Uncaria
GenisteinIRCT201312132480N53Oral supplementation of genistein (250 mg) for 8 wk can decrease insulin resistance, oxidative stress, and inflammation and improve lipid metabolism in patients with NAFLD
LactoferrinNCT04335058NoneTo test the effect of lactoferrin with iron versus iron alone in the treatment of anemia in CLD
SeleniumNCT00271245NoneTo test the effect of selenium in patients with cirrhosis
NCT016501814To test the impacts using siliphos-selenium-methionine-alpha lipoic acid plus metformin versus metformin in patients with fatty liver and NASH
SilymarinNCT003893761An increase in silymarin is observed in NAFLD patients, compared to that in patients with HCV
NCT006804072The effect of silymarin on NASH patients remains inconclusive due to the lack of a substantial number of patients
TelmisartanNCT022132244To evaluate the therapeutic effects of telmisartan and perindopril for NAFLD patients with hypertension